Literature DB >> 16292511

Aging-related correlation of insulin-degrading enzyme with gamma-secretase-generated products involving insulin and glucose levels in transgenic mice.

Dae Y Hwang1, Jung S Cho, Chuel K Kim, Sun B Shim, Seung W Jee, Su H Lee, Su J Seo, Joon Y Cho, Seok H Lee, Yong K Kim.   

Abstract

Insulin-degrading enzyme (IDE) is a 110-kDa thiol zinc-methalloendopeptidase that can cleave small Abeta peptides and the APP intracellular domain (AICD). The aim of this study was to examine aging-related correlation of IDE with gamma-secretase-generated products involving insulin and glucose levels in transgenic brains expressing neuron-specific enolase (NSE)-controlled human mutant presenilin-2 (hPS2m). Herein, we concluded that the levels of IDE expression in transgenic brains were decreased relative to those of control mice at 15 months of age. In parallel, inhibition in the IDE expression at this age underlies to the levels-up of Abeta-42, AICD, gamma-secretase, and glucose with a level-down of insulin. Thus, IDE expression is critical target for the therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16292511     DOI: 10.1007/s11064-005-7952-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  18 in total

1.  Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.

Authors:  M Hasan Mohajeri; M Axel Wollmer; Roger M Nitsch
Journal:  J Biol Chem       Date:  2002-07-08       Impact factor: 5.157

2.  Insulysin and pitrilysin: insulin-degrading enzymes of mammals and bacteria.

Authors:  A B Becker; R A Roth
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

3.  Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme.

Authors:  K Vekrellis; Z Ye; W Q Qiu; D Walsh; D Hartley; V Chesneau; M R Rosner; D J Selkoe
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

4.  Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation.

Authors:  W Xia; W J Ray; B L Ostaszewski; T Rahmati; W T Kimberly; M S Wolfe; J Zhang; A M Goate; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type.

Authors:  Y Fujisawa; K Sasaki; K Akiyama
Journal:  Biol Psychiatry       Date:  1991-12-15       Impact factor: 13.382

6.  Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity.

Authors:  I D Goldfine; J A Williams; A C Bailey; K Y Wong; Y Iwamoto; K Yokono; S Baba; R A Roth
Journal:  Diabetes       Date:  1984-01       Impact factor: 9.461

7.  Hyperinsulinaemia and Alzheimer's disease.

Authors:  G Razay; G K Wilcock
Journal:  Age Ageing       Date:  1994-09       Impact factor: 10.668

8.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Authors:  Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-12       Impact factor: 11.205

9.  Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging.

Authors:  Nobuhisa Iwata; Yoshie Takaki; Shinjiro Fukami; Satoshi Tsubuki; Takaomi C Saido
Journal:  J Neurosci Res       Date:  2002-11-01       Impact factor: 4.164

10.  Use of NSE/PS2m-transgenic mice in the study of the protective effect of exercise on Alzheimer's disease.

Authors:  Jun Y Cho; Dae Y Hwang; Tae S Kang; Dong H Shin; Jin H Hwang; Chae H Lim; Su H Lee; Hwa J Lim; Sae H Min; Su J Seo; Youn S Song; Ki T Nam; Kyu S Lee; Jung S Cho; Yong K Kim
Journal:  J Sports Sci       Date:  2003-11       Impact factor: 3.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.